Clinical, laboratory, radiological features, and outcome in 26 patients with aortic involvement amongst a case series of 63 patients with giant cell arteritis;Caractéristiques cliniques, paracliniques et profil évolutif de l'atteinte aortique de la maladie de Horton: À propos de 26cas d'aortite parmi 63cas de maladie de Horton

Revue de Medecine Interne

Volumn 35, Issue 1, 2014, Pages 4-15

  Daumas, A ^a,b   Rossi, P ^a,c   Bernard Guervilly, F ^a,c   Frances Y ^a,c   Berbis, J ^a,d   Durand, J M ^a,e   Kaplanski, G ^a,e   Ebbo, M ^a,e   Harle J R ^a,e   Weiller, P J ^a,b   Serratrice, J ^a,b   Disdier, P ^a,b   Gayet, S ^a,b   Villani, P ^a,b   Granel, B ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL NORD   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

18Ffluorodeoxyglucose positron emission tomography; Aortitis; Computed tomography scan; Giant cell arteritis; Large vessel vasculitis

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE;

AGED; AORTITIS; ARTERIAL WALL THICKNESS; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; GIANT CELL ARTERITIS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MAJOR CLINICAL STUDY; ONSET AGE; PATIENT MONITORING; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ANGIOSCOPY; AORTA; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOSCOPY; AORTA; AORTITIS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890796230     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.06.007     Document Type: Article

References (38)

1. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:318-323.
2. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Lopez-Diaz M.J., Miranda-Filloy J.A., Gonzalez-Juanatey C., Martin J., et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
3. Marie I. Maladie de Horton et pseudopolyarthrite rhizomélique: critères diagnostiques. Rev Med Interne 2013, 34:403-411.
4. Ly K.H., Liozon E., Fauchais A.L., Vidal E. PhysiopatHologie de l'artérite à cellules géantes. Rev Med Interne 2013, 34:392-402.
5. Sailler L., Pugnet G., Bienvenu B. Traitement de la maladie de Horton. Rev Med Interne 2013, 34:431-437.
6. Liozon E., Ly K.H., Robert P.Y. Manifestations ophtalmologiques de la maladie de Horton. Rev Med Interne 2013, 34:421-430.
7. Salvarani C., Pipitone N., Versari A., Hunder G.G. Clinical features of polymyalgia rheumatic and giant cell arteritis. Nat Rev Rheumatol 2012, 8:509-521.
8. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240patients. Medicine (Baltimore) 2005, 84:269-276.
9. Espitia O., Agard C. Aortite et complications aortiques de l'artérite à cellules géantes (maladie de Horton). Rev Med Interne 2013, 34:412-420.
10. Henriet J.P., Marin J., Gosselin J., Hamel-Desnos C., Ducrocq M., Brard G., et al. The history of Horton's disease or 10centuries of a fascinating adventure. J Mal Vasc 1989, 14(Suppl.C):93-97.
11. Marie I., Proux A., Duhaut P., Primard E., Lahaxe L., Girszyn N., et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48patients. Medicine (Baltimore) 2009, 88:182-192.
12. Launay D., Hachulla E. Inflammatory aortitis. Presse Med 2004, 33:1334-1340.
13. Blockmans D. Diagnosis and extension of giant cell arteritis. Contribution of imaging techniques. Presse Med 2012, 41:948-954.
14. NuenningHoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., Matteson E.L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50years. Arthritis Rheum 2003, 48:3532-3537.
15. Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995, 122:502-507.
16. NuenningHoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., Matteson E.L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large- artery stenosis) in patients with giant cell arteritis: a population-based study over 50years. Arthritis Rheum 2003, 48:3522-3531.
17. Gonzalez-Gay M.A., Garcia-Porrua C., Piñeiro A., Pego-Reigosa R., Llorca J., Hunder G.G. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004, 83:335-341.
18. García-Martínez A., Hernández-Rodríguez J., Arguis P., et al. Development of aortic aneurysm/dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008, 59:422-430.
19. Espitia O., Néel A., Leux C., Connault J., Espitia-Thibault A., Ponge T., et al. Giant cell arteritis with or witHout aortitis at diagnosis. A retrospective study of 22patients with long-term follow-up. J Rheumatol 2012, 39:2157-2162.
20. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-1128.
21. Hervé F., CHoussy V., Janvresse A., Cailleux N., Levesque H., Marie I. Aortic involvement in giant cell arteritis. A prospective follow-up of 11patients using computed tomography. Rev Med Interne 2006, 27:196-202.
22. The criteria committee of the New York Heart Association Diseases of the aorta. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels 1994, Little, Brown and Co, Boston. 9th ed.
23. Agard C., Barrier J.H., Dupas B., Ponge T., Mahr A., Fradet G., et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum 2008, 59:670-676.
24. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
25. Prieto-González S., Arguis P., García-Martínez A., Espígol-Frigolé G., Tavera-Bahillo I., Butjosa M., et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40newly diagnosed patients using CT angiography. Ann Rheum Dis 2012, 71:1170-1176.
26. Brack A., Martinez-Taboada V., Stanson A., Goronzy J.J., Weyand C.M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999, 42:311-317.
27. Assie C., Marie I. Giant cell arteritis-related upper/lower limb vasculitis. Presse Med 2011, 40:151-161.
28. Assie C., Janvresse A., Plissonnier D., Levesque H., Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36patients. Medicine (Baltimore) 2011, 90:40-51.
29. Klein R.G., Hunder G.G., Stanson A.W., Sheps S.G. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975, 83:806-812.
30. Berger C.T., Wolbers M., Meyer P., Daikeler T., Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 2009, 48:258-261.
31. Narváez J., Bernad B., Gómez-Vaquero C., García-Gómez C., Roig-Vilaseca D., Juanola X., et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008, 26(Suppl.49):S57-S62.
32. Benhamou Y., Lévesque H. Aspirin and temporal arteritis. J Mal Vasc 2005, 30:5-7.
33. Blockmans D., Coudyzer W., Vanderschueren S., Stroobants S., Loeckx D., Heye S., et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 2008, 47:1179-1184.
34. 18FDG dans l'exploration et la surveillance des vascularites. Rev Med Interne 2010, 31:417-427.
35. Blockmans D., de Ceuninck L., Vanderschueren S., Knockaert D., Mortelmans L., Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35patients. Arthritis Rheum 2006, 55:131-137.
36. Karsenty H.A., Billotey C., Monard E., Mausservey C., Coppere B., Perard L., et al. Intérêt du PET-scan dans les atteintes inflammatoires de l'aorte. Rev Med Interne 2009, 30(Suppl.):365.
37. Both M., Ahmadi-Simab K., Reuter M., Dourvos O., Fritzer E., Ullrich S., et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis 2008, 67:1030-1033.
38. Narváez J., Narváez J.A., Nolla J.M., Sirvent E., Reina D., Valverde J. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology (Oxford) 2005, 44:479-483.